Four Bidan HA Fillers Win Indonesian Authorization
Aribio and Aribio Lab received final BPOM marketing authorization in Indonesia for four Bidan hyaluronic acid fillers.
This article was automatically drafted and passed editorial compliance checks. It synthesizes public source metadata and is not a substitute for individual care or clinical review.
Aribio and Aribio Lab announced on September 8, 2026, that Indonesia's food and drug authority, BPOM, had granted final marketing authorization to four products in their Bidan hyaluronic acid filler range.
The companies developed Bidan over seven years in connection with a university hospital, targeting the anti-aging and medical aesthetics market. Aribio said its Precise Control Refinement Technique, or PCRT, is used to produce smooth, uniform hyaluronic acid particles.
What the authorization changes
BPOM authorization clears a regulatory step for introducing the four Bidan fillers in Indonesia. Aribio and Aribio Lab said they have begun discussions with a local aesthetics company about product supply and launch.
The companies plan to build a distribution network with a local partner and proceed with entry into Indonesia's filler market. The event concerns Indonesian authorization and planned commercialization, rather than a newly reported treatment result.
Clinical context and reporting limits
Regulatory authorization is distinct from deciding whether a filler suits a particular person or treatment area. A qualified physician should assess individual variation, treatment goals, medical history, possible side effects, and recovery considerations before use.
The two Korean medical outlets did not report exact effectiveness rates, adverse-event frequencies, recovery timelines, prices, or an Indonesian launch date. Their coverage supports the authorization, development, technology, and market-entry facts, but not individualized outcome claims.
Questions for a consultation
Ask the clinician which specific product is being considered, why it fits the proposed area, and whether it has authorization in the country where treatment will occur. Four products share the Bidan brand name, so the exact product should be identified.
Patients should also consult the clinician about alternatives, expected individual variation, possible side effects, warning signs, aftercare, and recovery. These questions connect a regulatory announcement to the separate clinical decision required for an individual patient.
Frequently asked questions
Is Bidan filler authorized in Indonesia?
Yes. Aribio and Aribio Lab said BPOM granted final Indonesian marketing authorization to four Bidan hyaluronic acid filler products.
Does the authorization cover one product or several?
It covers four products under the Bidan brand. The reports do not identify the individual product names, so patients should consult a qualified physician about the exact product being considered.
When will Bidan launch in Indonesia?
No launch date was reported. Aribio and Aribio Lab said discussions had begun with a local aesthetics company about supply and launch, alongside plans to establish distribution with a local partner.
HA filler consultation checklist
- Which of the four Bidan products are you considering, and why?
- Is that exact product authorized where my treatment would take place?
- What side effects and warning signs should I know about?
- How could individual variation affect the plan and expected recovery?
- What alternatives and aftercare steps should we discuss?
MediIndex articles are for general information only and are not medical advice, diagnosis, or advertising. Outcomes vary by individual — consult a board-certified specialist for personal decisions.
